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Abstract: Insulin glulisine is appealing in principle, but the advantages of this drug over the 
other rapid-acting insulin analogs are still relatively unknown. The frequency of hypoglycemia, 
convenience in the timing of administration, and improvements in terms of HbA1c seem similar 
among the rapid-acting insulin analogs, including insulin glulisine. Only properly randomized long-
term clinical studies with insulin glulisine will reveal the true value of this novel insulin analog.
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Background
The discover of insulin in 1921 introduced a new era for the treatment of diabetes. After the 
DCCT study was reported in 19931 and the UKPDS was reported in 1998,2,3 it was assumed 
that tight glycemic control is important to prevent diabetic complications in both type 1 
and type 2 diabetes. Because the ACCORD study4 showed the difficulties in achieving 
tight glycemic control without harmful hypoglycemic episodes and the ADVANCE5 
and VADT6 studies revealed the difficulties in preventing cardiovascular complications, 
patients with diabetes need more effective and safer treatment strategies.
Type 2 diabetes is a progressive disease characterized by relentless deterioration 
of pancreatic beta cell function,7 and the incidence of type 2 diabetes is increasing, 
particularly in younger individuals.8 These facts suggest that an increasing number of 
patients with type 2 diabetes will ultimately require insulin therapy. Therefore, insulin 
analogs have been developed to mimic physiological insulin action, which allow tighter 
glycemic control with reduced risk of severe hypoglycemic episodes and offer good 
quality of life (QOL) in the absence of complications.
Development of insulin analogs
Figure 1a shows the molecular structure of insulin, which has a molecular weight of 
about 6000 kDa and consists of an A chain with 21 amino acids and a B chain with 
30 amino acids.9
The N-terminal of the A chain and the C-terminal of the B chain are the sites that bind 
to the insulin receptor. Thus, substitution in these amino acids will alter the avidity to the 
insulin receptor and the activity of the analog as an insulin receptor agonist. In addition, 
insulin forms stabile hexamers centered on Zn in solution. When this hexamer is injected 
subcutaneously, at first it will be resolved to a dimer and then a monomer, which is the 
absorbable form. The C-terminal of the B chain is critical in the formation of the dimer. 
Thus, substitution of amino acids in this area affects the conversion from the hexamer to Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 112
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the monomer and may aid rapid absorption. So far, three kinds 
of rapid-acting insulin analog have been introduced, namely 
insulin lispro, insulin aspart and insulin glulisine.
In insulin lispro, the natural sequence of proline at position 
B28 and lysine at position B29 is reversed (Figure 1b).10 
In insulin aspart, the natural sequence of proline at position B28 
is substituted by aspartic acid (Figure 1c).11 As these changes 
suggest, position B28 is a locus involved in dimer formation.
Structure of insulin glulisine
In insulin glulisine, the natural sequence of  asparagine at 
position B3 and lysine at position B29 are substituted by 
lysine and glutamic acid, respectively (Figure 1d).12,13 This 
structure of insulin glulisine affects not only self-association 
but also the isoelectric point, which is shifted lower (pH 5.1; 
human insulin, pH 5.5), which enhances its solubility at a 
physiologic pH. As a consequence, unlike other insulin 
analogs that lack proline at B28, insulin glulisine is more 
likely to self-associate into dimers in the absence of ligands. 
Thus, there are several important differences between insulin 
glulisine and the other rapid-acting insulin analogs, insulin 
lispro and insulin aspart (Table 1). The insulin glulisine 
solution does not contain hexamer-promoting Zn, but does 
include polysorbate 20 as a stabilizer and trometamol as a 
buffer. Polysorbate 20 is also known commercially as Tween 
20. This is used as an excipient in pharmaceutical applica-
tions to stabilize emulsions and suspensions. Purified protein 
derivative (PPD) solution, which contains polysorbate 20, is 
used in skin testing for tuberculosis exposure. Trometamol 
is known as Tris or THAM and is extensively used in 
biochemistry and molecular biology. In a clinical setting, 
trometamol is used as an alternative to sodium bicarbonate 
Figure 1 The amino acid sequence of human insulin and rapid-acting insulin analogs. Pink circles: amino acid residues involved in dimer formation. Blue circles: amino acid 
residues involved in hexamer formation.   Arrow: amino acid residues involved in binding with the insulin receptor. A) human insulin, B) insulin lispro, C) insulin aspart, and 
D) insulin glulisine.
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for the treatment of metabolic acidosis. Although the clinical 
effects of long-term administration of polysorbate 20 and 
trometamol are unknown, no Zn must be helpful because 
this allows more rapid absorption.
Pharmacokinetics and biologic 
actions of insulin glulisine
Pharmacokinetic studies with insulin glulisine have shown 
an absorption profile with a peak insulin concentration that is 
approximately twice that of regular human insulin, and which 
is reached in approximately half the time. Compared with 
insulin lispro, several studies14–16 have shown a faster onset 
of action for insulin glulisine. So far, no study has directly 
compared the pharmacokinetics of insulin aspart and insulin 
glulisine. However, Homko et al described similar pharma-
cokinetics and metabolic effects of insulin lispro and insulin 
aspart.17 Accordingly, insulin glulisine may have the most 
rapid onset of action of the rapid-acting insulin analogs. But, in 
terms of the metabolic effect, Horvath et al showed that insulin 
glulisine, insulin lispro, and regular insulin have similar effects 
on hepatic glucose production and glucose uptake.18
According to a review of the clinical pharmacokinetics and 
pharmacodynamics of insulin glulisine,12 dose proportionality 
in early, maximum and total exposure is observed for insulin 
glulisine over the therapeutic relevant dose range up to 0.4 U/kg. 
The pharmacodynamic profile of insulin glulisine reflects the 
absorption kinetics by demonstrating a greater rate of glucose 
utilization, which is completed earlier and at equipotency 
on a molar base compared with regular human insulin.12 
Dose proportionality in glucose utilization has been established 
for insulin glulisine in patients with type 1 diabetes in the dose 
range of 0.075 to 0.15 U/kg, and with less intra-subject variability 
compared with insulin lispro and regular human insulin.12
Clinical studies of insulin glulisine
Glycemic control
In general, the history of insulin glulisine is short and clinical 
studies are few. First, therefore, the rapid-acting insulin 
analogs should be described. The effects of rapid-acting 
insulin analogs on HbA1c levels have been reviewed system-
atically and meta-analyzed.19 In that review of 49 randomized 
clinical studies comparing rapid-acting insulin analogs with 
regular human insulin, a weighted mean difference in HbA1c 
of  -0.1% was determined in favor of analogs in patients with 
type 1 diabetes. Among patients with type 2 diabetes, there 
was no difference in HbA1c between rapid-acting analogs 
and regular human insulin. But, only one study used insulin 
glulisine (37 studies used insulin lispro, 10 used insulin 
aspart, one used insulin lispro and insulin aspart).20 In that 
study, Garg et al showed that injection of insulin glulisine 
0–15 minutes before meals (n = 268) reduced HbA1c (-0.26%) 
more than the injection of regular insulin 30–45 minutes 
before meals (n = 257) (–0.13%) in type 1 diabetes.20
Furthermore, Dailey et al reported that insulin glu-
lisine (n = 435) provided a slightly greater reduction in 
HbA1c (-0.46%) than regular insulin (n = 441) (-0.30%) in 
Table 1 Comparison of regular human insulin and rapid-acting insulin analogs
Human insulin Insulin lispro Insulin aspart Insulin glulisine
insulin action Onset min 30–60 5–15 5–15 5–15
Peak h 2–3 0.5–1.5 0.5–1.5 0.5–1.5
Cmax µg/L 0.6–2.5 0.8–4.1
pmol/L 195–260 341–506
mU/L 40 ± 10 73 ± 16
ratio 100 222 175 183
Duration hr 6–10 4–5 4–5 4–5
excipients Zinc + + + –
Polysorbate 20 – – – +
Trometamol – – – +
receptor binding and  
mitogenic potencies
Insulin receptor affinity (%) 100 84 ± 6 92 ± 6 68–71
Insulin receptor off-rate (%) 100 100 ± 11 81 ± 8 n.a.
Metabolic potency (%) 100 82 ± 3 101 ± 2 44–45
IGF-1 receptor affinity (%) 100 156 ± 16 81 ± 9 16.2 
Mitogenic potency (%) 100 66 ± 10 58 ± 22 Nearly100Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 114
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type 2 diabetes.21 There were no between-group differences 
in baseline-to-end point changes in insulin dose.
On the other hand, Dreyer et al reported similar reductions 
in HbA1c (–0.14%) with insulin glulisine and insulin lispro 
over a 26-week study in patients with type 1 diabetes (insulin 
glulisine, n = 339; insulin lispro, n = 333).22 In that study, 
there was a significant difference in changes in daily dose of 
insulin; –0.86 U in the insulin glulisine group and +1.01 U 
in the insulin lispro group.
Meanwhile, Hoogma et al described that insulin glulisine 
can be safely used in continuous subcutaneous insulin 
infusion (CSII) and does not have any adverse clinical impli-
cations compared with insulin aspart.23 These data suggest 
that insulin glulisine may be useful in achieving glycemic 
control that is greater than that with regular insulin and 
similar to that with the other rapid-acting insulin analogs.
Hypoglycemia
In terms of hypoglycemia, the Cochrane review of clinical stud-
ies found a lower incidence of severe hypoglycemic episodes 
with rapid-acting insulin analogs (median 21.8 episodes per 
100 person-years in type 1 diabetes and 0.3 in type 2 diabetes) 
compared with regular insulin (median 46.1 episodes per 
100 person-years in type 1 diabetes and 1.4 in type 2 diabetes).19 
Although only one study using insulin glulisine was included 
in that review, the study by Garg et al showed a non-significant 
reduction in severe hypoglycemic episodes in the insulin glulisine 
groups (8.4% with premeal insulin glulisine and 8.4% with post-
meal insulin glulisine vs 10.1% with premeal regular insulin).20
Dailey et al reported that the proportion of patients with 
serious hypoglycemia was comparable between the insulin gluli-
sine (n = 15, 3.4%) and regular insulin (n = 11, 2.5%) groups. The 
adjusted mean change in body weight was also similar in both 
treatment groups (glulisine, 1.8 kg; regular insulin, 2.0 kg).21
In Dreyer’s study, the hypoglycemic episodes were compa-
rable between insulin glulisine and insulin lispro; 3.64 ± 4.49 
symptomatic hypoglycemic events per patient-month with insu-
lin glulisine and 3.48 ± 4.38 with insulin lispro; the respective 
rates for severe hypoglycemia were 0.03 ± 0.12 and 0.02 ± 0.11 
events per patient-month and for nocturnal hypoglycemia were 
0.55 ± 0.94 and 0.53 ± 0.84 events per patient-month.22
These data suggest that, at least, insulin glulisine does not 
increase hypoglycemia compared with the other short-acting 
insulin products.
Quality of life
I searched Medline for published articles with terms related 
to “glulisine” and “quality-of-life”. Although this search 
provided 8 articles, there was no original research article. 
Therefore, I describe the rapid-acting insulin analogs on 
quality-of life. In terms of quality of life and treatment sat-
isfaction, only 12 of the 49 studies assessed in the Cochrane 
review included reported these data. Of these 12 studies, 
7 used the Diabetes Treatment Satisfaction Questionnaire 
(DTSQ);19 3 studies found no significant difference in DTSQ 
between the treatment arms,24–26 and 4 studies showed an 
improvement in the analog group.27–30
immunogenicity and safety
Because the history of insulin glulisine is still limited, I can-
not describe its immunogenicity. For insulin lispro and insulin 
aspart, the structural changes were initially reported to result in 
decreased immunogenicity in in vivo studies.9,31 However, recent 
studies of insulin allergy demonstrated the existence of clinical 
allergy to these new insulin analogs and to regular insulin.32–34 
Because insulin glulisine contains polysorbate 20 and trometamol 
as well as structural changes, one may anticipate different 
immunogenicity profiles compared with regular insulin.
Use of insulin glulisine  
in clinical settings
So far, there are few clinical studies of insulin glulisine. Firm 
conclusions cannot therefore be made on the utility of this 
new insulin analog. However, as mentioned above, insulin 
glulisine appears to have the most rapid onset of action of the 
insulin analogs and, in addition, may provide better glycemic 
control and reduced risk of hypoglycemia compared with 
regular insulin. This new insulin analog may be particularly 
useful in patients with high risk of hypoglycemia or insulin 
allergy and could also be a useful insulin to be considered for 
insulin pump therapy. In the future, more clinical use and good 
randomized long-term clinical studies with insulin glulisine 
will reveal the true value of this novel insulin analog.
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